|Title:||Administration of monoamine acridines in cholinergic neuronal deficit states|
|Abstract:||A method for treating central nervous system or peripheral nervous system cholinergic deficit states such as Alzheimer's disease in a mammal, said method comprising administering to said mammal an amount of a monoamine acridine derivative effective in the treatment of a cholinergic deficit state and for a time sufficient to achieve a suitable blood level to treat said cholinergic deficit state. The preferred monoamine acridine derivative is 1,2,3,4-tetrahydro-5-aminoacridine. A unit dosage pharmaceutical composition of matter comprising an effective amount of said monoamine acridine derivative sufficient to treat said cholinergic deficit state and a pharmaceutically acceptable inert carrier therefor is also disclosed.|
|Inventor(s):||Summers; William K. (Arcadia, CA)|
Patent Claim Types:|
see list of patent claims
|Use; Delivery; Composition; Compound; Dosage form;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.